Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
A Placebo Controlled, Parallel Group, Randomised Withdrawal Study of Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Who Are Receiving Long-term Sativex®.
Sponsor: Jazz Pharmaceuticals
This PHASE3 trial investigates Multiple Sclerosis and Spasticity and is currently completed. Jazz Pharmaceuticals leads this study, which shows 10 recorded versions since 2007 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jun 2023 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Mar 2022 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jazz Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .